American Century Companies Inc. Increases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

American Century Companies Inc. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 30.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 809,814 shares of the company's stock after purchasing an additional 191,385 shares during the period. American Century Companies Inc. owned 0.99% of IDEXX Laboratories worth $334,810,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Cranbrook Wealth Management LLC raised its stake in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after purchasing an additional 25 shares in the last quarter. Perigon Wealth Management LLC raised its position in shares of IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after buying an additional 26 shares in the last quarter. Summit Trail Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after acquiring an additional 26 shares during the last quarter. First Horizon Advisors Inc. grew its position in IDEXX Laboratories by 4.0% in the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock worth $356,000 after acquiring an additional 27 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its stake in IDEXX Laboratories by 4.4% in the third quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company's stock valued at $375,000 after acquiring an additional 31 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Trading Up 0.0 %

Shares of NASDAQ IDXX traded up $0.05 during trading hours on Wednesday, hitting $417.71. The company's stock had a trading volume of 760,713 shares, compared to its average volume of 555,674. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The stock has a market cap of $33.86 billion, a price-to-earnings ratio of 39.15, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The business has a 50-day simple moving average of $437.36 and a 200-day simple moving average of $444.05.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.